Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

L-DOPA

From Wikipedia, the free encyclopedia
Chemical compound
This article is aboutL-DOPA as a biological compound. For its role as a medication and supplement, seeLevodopa.

L-DOPA
Names
IUPAC name
(S)-2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
Other names
l-3,4-Dihydroxyphenylalanine; Levodopa
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard100.000.405Edit this at Wikidata
EC Number
  • 200-445-2
KEGG
UNII
  • InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1
    Key: WTDRDQBEARUVNC-LURJTMIESA-N
  • C1=CC(=C(C=C1C[C@@H](C(=O)O)N)O)O
Properties
C9H11NO4
Molar mass197.19 g/mol
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa).
Chemical compound

l-DOPA, also known asl-3,4-dihydroxyphenylalanine and used medically aslevodopa, is made and used as part of the normalbiology of some plants[2] and animals, including humans. Humans, as well as a portion of the other animals that utilizel-DOPA, make it viabiosynthesis from theamino acidl-tyrosine.

l-DOPA is theprecursor to theneurotransmittersdopamine,norepinephrine (noradrenaline), andepinephrine (adrenaline), which are collectively known ascatecholamines. Furthermore,l-DOPA itself mediatesneurotrophic factor release by the brain andcentral nervous system.[3][4] In some plant families (of the orderCaryophyllales),l-DOPA is the central precursor of a biosynthetic pathway that produces a class of pigments calledbetalains.[5]

l-DOPA can be manufactured and in its pure form is sold as adrug with theINNTooltip International Nonproprietary Namelevodopa. As a drug, it is used in thetreatment ofParkinson's disease anddopamine-responsive dystonia, as well asrestless leg syndrome.[6]

l-DOPA has a counterpart with oppositechirality,d-DOPA. As is true for many molecules, the human body produces only one of theseisomers (thel-DOPA form). Theenantiomeric purity ofl-DOPA may be analyzed by determination of the optical rotation or by chiralthin-layer chromatography.[7]

Biological role

[edit]

l-DOPA is produced from the amino acidl-tyrosine by the enzymetyrosine hydroxylase.l-DOPA can act as anl-tyrosine mimetic and be incorporated into proteins by mammalian cells in place ofl-tyrosine, generatingprotease-resistant andaggregate-prone proteinsin vitro and may contribute toneurotoxicity with chronicl-DOPA administration.[11]It is also the precursor for themonoamine orcatecholamine neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline). Dopamine is formed by the decarboxylation ofl-DOPA byaromaticl-amino acid decarboxylase (AADC).

l-DOPA can be directly metabolized bycatechol-O-methyl transferase to3-O-methyldopa, and then further tovanillactic acid. This metabolic pathway is nonexistent in the healthy body, but becomes important after peripherall-DOPA administration in patients with Parkinson's disease or in the rare cases of patients with AADC enzyme deficiency.[12]

l-Phenylalanine,l-tyrosine, andl-DOPA are all precursors to the biologicalpigmentmelanin. The enzymetyrosinasecatalyzes theoxidation ofl-DOPA to the reactive intermediatedopaquinone, which reacts further, eventually leading to melaninoligomers. In addition,tyrosinase can convert tyrosine directly tol-DOPA in the presence of a reducing agent such asascorbic acid.[13]

Chemistry

[edit]

L-DOPA, also known asL-3,4-dihydroxyphenylalanine orL-3-hydroxytyrosine, is anaromatic amino acid derived fromL-phenylalanine andL-tyrosine. It is aphenethylamine,monoamine, andcatecholamine, and is abiological precursor of theneurotransmittersdopamine (3,4-dihydroxyphenethylamine),norepinephrine (3,4,β-trihydroxyphenethylamine), andepinephrine (3,4,β-trihydroxy-N-methylphenethylamine).

Synthesis

[edit]
Synthesis ofl-DOPA via hydrogenation with C2-symmetric diphosphine.

History

[edit]

l-DOPA was first isolated from the seeds of theVicia faba (broad bean) plant in 1913 by Swiss biochemist Markus Guggenheim.[14]

The 2001Nobel Prize in Chemistry was also related tol-DOPA: the Nobel Committee awarded one-quarter of the prize toWilliam S. Knowles for his work on chirally catalysedhydrogenation reactions, the most noted example of which was used for the synthesis ofl-DOPA.[15][16][17]

Other organisms

[edit]

Marine adhesion

[edit]

l-DOPA is a keycompound in the formation ofmarine adhesive proteins, such as those found inmussels.[18][19] It is believed to be responsible for the water-resistance and rapid curing abilities of these proteins.l-DOPA may also be used to prevent surfaces from fouling by bonding antifouling polymers to a susceptiblesubstrate.[20] The versatile chemistry ofl-DOPA can be exploited in nanotechnology.[21] For example, DOPA-containing self-assembling peptides were found to form functional nanostructures, adhesives and gels.[22][23][24][25]

Plants and in the environment

[edit]

In plants,L-DOPA functions as anallelochemical which inhibits the growth of certain species, and is produced and secreted by a few legume species such as the broad beanVicia faba and the velvet beanMucuna pruriens.[26] Its effect is strongly dependent on the pH and the reactivity of iron in the soil.[27]L-DOPA can also be found incephalopod ink.[28]

Use as a medication and supplement

[edit]
Main article:Levodopa

L-DOPA is used medically under the namelevodopa in the treatment ofParkinson's disease and certain other medical conditions. It is usually used incombination with aperipherally selectivearomaticL-amino acid decarboxylase (AAAD)inhibitor such ascarbidopa orbenserazide. These agents increase the strength and duration of levodopa. Combination formulations includelevodopa/carbidopa andlevodopa/benserazide, as well aslevodopa/carbidopa/entacapone.

L-DOPA is found in high amounts inMucuna pruriens (velvet bean) and is available and usedover-the-counter as asupplement.

References

[edit]
  1. ^Howard ST, Hursthouse MB, Lehmann CW, Poyner EA (1995). "Experimental and theoretical determination of electronic properties in Ldopa".Acta Crystallogr. B.51 (3):328–337.Bibcode:1995AcCrB..51..328H.doi:10.1107/S0108768194011407.S2CID 96802274.
  2. ^Cohen PA, Avula B, Katragunta K, Khan I (October 2022)."Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database".JAMA Neurology.79 (10):1085–1086.doi:10.1001/jamaneurol.2022.2184.PMC 9361182.PMID 35939305.
  3. ^Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS (September 2008)."L-DOPA is an endogenous ligand for OA1".PLOS Biology.6 (9) e236.doi:10.1371/journal.pbio.0060236.PMC 2553842.PMID 18828673.
  4. ^Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, et al. (January 2014)."The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii".British Journal of Pharmacology.171 (2):403–14.doi:10.1111/bph.12459.PMC 3904260.PMID 24117106.
  5. ^Polturak G, Breitel D, Grossman N, Sarrion-Perdigones A, Weithorn E, Pliner M, et al. (2016)."Elucidation of the first committed step in betalain biosynthesis enables the heterologous engineering of betalain pigments in plants".New Phytol.210 (1):269–283.Bibcode:2016NewPh.210..269P.doi:10.1111/nph.13796.hdl:10251/87415.PMID 26683006.
  6. ^Scholz H, Trenkwalder C, Kohnen R, Kriston L, Riemann D, Hornyak M (15 February 2011)."Levodopa for the treatment of restless legs syndrome".Cochrane Database of Systematic Reviews.2011 (5) CD005504.doi:10.1002/14651858.CD005504.pub2.PMC 8889887.PMID 21328278.S2CID 196338172.
  7. ^Martens J, Günther K, Schickedanz M (1986). "Resolution of Optical Isomers by Thin-Layer Chromatography: Enantiomeric Purity of Methyldopa".Arch. Pharm.319 (6):572–574.doi:10.1002/ardp.19863190618.S2CID 97903386.
  8. ^Broadley KJ (March 2010). "The vascular effects of trace amines and amphetamines".Pharmacology & Therapeutics.125 (3):363–375.doi:10.1016/j.pharmthera.2009.11.005.PMID 19948186.
  9. ^Lindemann L, Hoener MC (May 2005). "A renaissance in trace amines inspired by a novel GPCR family".Trends in Pharmacological Sciences.26 (5):274–281.doi:10.1016/j.tips.2005.03.007.PMID 15860375.
  10. ^Wang X, Li J, Dong G, Yue J (February 2014). "The endogenous substrates of brain CYP2D".European Journal of Pharmacology.724:211–218.doi:10.1016/j.ejphar.2013.12.025.PMID 24374199.
  11. ^Rodgers KJ (March 2014). "Non-protein amino acids and neurodegeneration: the enemy within".Experimental Neurology.253:192–196.doi:10.1016/j.expneurol.2013.12.010.PMID 24374297.S2CID 2288729.
  12. ^Hyland K, Clayton PT (December 1992)."Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology"(PDF).Clinical Chemistry.38 (12):2405–10.doi:10.1093/clinchem/38.12.2405.PMID 1281049. Archived fromthe original(PDF) on 7 June 2011. Retrieved16 October 2008.
  13. ^Ito S, Kato T, Shinpo K, Fujita K (September 1984)."Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine".The Biochemical Journal.222 (2):407–11.doi:10.1042/bj2220407.PMC 1144193.PMID 6433900.
  14. ^Ovallath S, Sulthana B (2017)."Levodopa: History and Therapeutic Applications".Annals of Indian Academy of Neurology.20 (3):185–189.doi:10.4103/aian.AIAN_241_17.PMC 5586109.PMID 28904446.
  15. ^Knowles WS (1983). "Asymmetric hydrogenation".Accounts of Chemical Research.16 (3):106–112.doi:10.1021/ar00087a006.
  16. ^"Synthetic scheme for total synthesis of DOPA, L- (Monsanto)". UW Madison, Department of Chemistry. Retrieved30 September 2013.
  17. ^Knowles WS (March 1986). "Application of organometallic catalysis to the commercial production of L-DOPA".Journal of Chemical Education.63 (3): 222.Bibcode:1986JChEd..63..222K.doi:10.1021/ed063p222.
  18. ^Waite JH, Andersen NH, Jewhurst S, Sun C (2005). "Mussel Adhesion: Finding the Tricks Worth Mimicking".J Adhesion.81 (3–4):1–21.doi:10.1080/00218460590944602.S2CID 136967853.
  19. ^"Study Reveals Details Of Mussels' Tenacious Bonds". Science Daily. 16 August 2006. Retrieved30 September 2013.
  20. ^"Mussel Adhesive Protein Mimetics". Archived fromthe original on 29 May 2006.
  21. ^Giuri D, Ravarino P, Tomasini C (June 2021). "L-Dopa in small peptides: an amazing functionality to form supramolecular materials".Organic & Biomolecular Chemistry.19 (21):4622–4636.doi:10.1039/D1OB00378J.hdl:11585/840774.PMID 33978030.S2CID 234474122.
  22. ^Fichman G, Adler-Abramovich L, Manohar S, Mironi-Harpaz I, Guterman T, Seliktar D, et al. (July 2014)."Seamless metallic coating and surface adhesion of self-assembled bioinspired nanostructures based on di-(3,4-dihydroxy-L-phenylalanine) peptide motif".ACS Nano.8 (7):7220–7228.Bibcode:2014ACSNa...8.7220F.doi:10.1021/nn502240r.PMC 4108209.PMID 24936704.
  23. ^Fichman G, Guterman T, Adler-Abramovich L, Gazit E (August 2014)."The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies".Nanomaterials.4 (3):726–740.doi:10.3390/nano4030726.PMC 5304689.PMID 28344244.
  24. ^Fichman G, Andrews C, Patel NL, Schneider JP (October 2021)."Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide".Advanced Materials.33 (40) 2103677: e2103677.Bibcode:2021AdM....3303677F.doi:10.1002/adma.202103677.PMC 8492546.PMID 34423482.{{cite journal}}: CS1 maint: article number as page number (link)
  25. ^Maity S, Nir S, Zada T, Reches M (October 2014). "Self-assembly of a tripeptide into a functional coating that resists fouling".Chemical Communications.50 (76):11154–11157.doi:10.1039/C4CC03578J.PMID 25110984.
  26. ^Fujii Y, Shibuya T, Yasuda T (1991)."L-3,4-Dihydroxyphenylalanine as an Allelochemical Candidate from Mucuna pruriens (L.) DC. var. utilis".Agricultural and Biological Chemistry.55 (2):617–618.doi:10.1080/00021369.1991.10870627.
  27. ^Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023)."L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner".Botanical Studies.64 (24) 24:617–618.Bibcode:2023BotSt..64...24H.doi:10.1186/s40529-023-00396-7.PMC 10449704.PMID 37620733.
  28. ^Lucero MT, Farrington H, Gilly WF (August 1994). "Quantification of L-Dopa and Dopamine in Squid Ink: Implications for Chemoreception".The Biological Bulletin.187 (1):55–63.doi:10.2307/1542165.ISSN 1939-8697.JSTOR 1542165.PMID 29281314.
Types
Vitamins and
chemical elements
("minerals")
Other common
ingredients
Related articles
General topics
Unspecified L-amino acid
By properties
Aliphatic
Aromatic
Polar, uncharged
Positive charge (pKa)
Negative charge (pKa)
Essential amino acids are in Capitals
Kacetyl-CoA
LYSINE
LEUCINE
TRYPTOPHAN
PHENYLALANINEtyrosine
  • (see below)
G
G→pyruvate
citrate
glycineserine
alanine
cysteine
threonine
G→glutamate
α-ketoglutarate
HISTIDINE
proline
arginine
alpha-ketoglutarate→TCA
Other
G→propionyl-CoA
succinyl-CoA
VALINE
ISOLEUCINE
METHIONINE
THREONINE
succinyl-CoA→TCA
G→fumarate
PHENYLALANINEtyrosine
G→oxaloacetate
asparagineaspartate
Catecholamines
Anabolism
Catabolism
Dopamine
Norepinephrine
Epinephrine
TryptophanSerotonin
Anabolism
Catabolism
SerotoninMelatonin
Trace amines
Histamine
GABA
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=L-DOPA&oldid=1316252618"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp